A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based on our proprietary Tri-specific Killer Engager (“TriKE®”), and Tetra-specific Killer Engager (“Dual Targeting TriKE®”) fusion protein immune cell engager technology platforms. Our TriKE® and Dual Targeting TriKE® platforms generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer cells (“NK cells”). Once bound to an NK cell, our moieties are designed to activate the NK cell to direct it to one or more specifically targeted proteins expressed on a specific type of cancer cell or virus infected cell, resulting in the targeted cell’s death. TriKE®s can be designed to target any number of tumor antigens, including B7-H3, HER2, CD33 and PDL1, on hematologic malignancies or solid tumors and do not require patient-specific customization.
| Metric | TTM | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | - |
| Net Income | -34M | -28M | -39M | -144M | - | -21M |
| EPS | $-6.68 | $-3,289.50 | $-341.70 | $-4,386.00 | $61,154.10 | $-4,569.60 |
| Free Cash Flow | 0 | -7.3M | -3.7M | -5.4M | -1.9M | -4.7M |
| ROIC | -121.1% | -94.4% | - | -53.3% | - | -13059.9% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -1.05 | -0.70 | - | -0.55 | -0.08 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -12M | -6.8M | - | -136M | -9.4M | -8.9M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -595.3% | - | - | - | - | - |
| Shares Outstanding | 32M | 0M | 0M | 0M | 0M | 0M |
GT Biopharma, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
GT Biopharma, Inc. (GTBP) has a 5-year average return on invested capital (ROIC) of -73.8%. This is below average and may indicate limited pricing power.
GT Biopharma, Inc. (GTBP) has a market capitalization of $12M. It is classified as a small-cap stock.
GT Biopharma, Inc. (GTBP) does not currently pay a regular dividend.
GT Biopharma, Inc. (GTBP) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
GT Biopharma, Inc. (GTBP) generated $-7 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
GT Biopharma, Inc. (GTBP) reported earnings per share (EPS) of $-3289.50 in its most recent fiscal year.
The Ledger Terminal provides 10 years of financial data for GT Biopharma, Inc. (GTBP), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
GT Biopharma, Inc. (GTBP) has a book value per share of $-3421.68, based on its most recent annual SEC filing.